* MaxCyte Inc MXCT.OQ MXCT.O is expected to show a fall
in
quarterly revenue when it reports results on August 6 for the
period ending June 30 2024
* The Rockville Maryland-based company is expected to
report a
12.4% decrease in revenue to $7.923 million from $9.04 million a
year ago, according to the mean estimate from 6 analysts, based
on LSEG data.
* LSEG's mean analyst estimate for MaxCyte Inc is for a
loss
of 13 cents per share.
* The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 6 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for MaxCyte Inc
is
$9.50, above its last closing price of $4.57.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Mar. 31 2024 -0.13 -0.13 -0.09 Beat 30.8
Dec. 31 2024 -0.07 -0.07 -0.05 Beat 30.6
Sep. 30 2023 -0.10 -0.10 -0.11 Missed -7.8
Jan. 1 0001 -0.10 -0.10 -0.10 Met -4.2
Mar. -0.11 -0.11 -0.11 Met 28.6
31 2023
Jan. 1 0001 -0.07 -0.05 Beat 28.6
Sep. 30 2022 -0.09 -0.08 -0.06 Beat 26.8
Jan. 1 0001 -0.09 -0.08 -0.08 Met 0
This summary was machine generated August 2 at 22:33 GMT. All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)